Unlocking the Potential of Phyto Nanotherapeutics in Hepatocellular Carcinoma Treatment: A Review
Manjusha Bhange,Darshan Telange
DOI: https://doi.org/10.2147/jhc.s483619
2024-11-24
Journal of Hepatocellular Carcinoma
Abstract:Manjusha Bhange, Darshan R Telange Department of Pharmaceutics, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education & Research (DU), Wardha, Maharashtra, India Correspondence: Manjusha Bhange, Department of Pharmaceutics, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education & Research (DU), Sawangi Meghe, Wardha, 442001, Maharashtra, India, Tel +91-9503985404, Email Hepatocellular carcinoma is the fifth leading cancer in related diseases most commonly in men and women. The curative treatments of liver cancer are short-listed, associated with toxicities and therapeutically. Emerging nanotechnologies exhibited the possibility to treat or target liver cancer. Over the years, to phytosome solid lipid nanoparticles, gold, silver, liposomes, and phospholipid nanoparticles have been produced for liver cancer therapy, and some evidence of their effectiveness has been established. Ideas are limited to the laboratory scale, and in order to develop active targeting of nanomedicine for the clinical aspects, they must be extended to a larger scale. Thus, the current review focuses on previously and presently published research on the creation of phytosomal nanocarriers for the treatment of hepatocellular carcinoma. In hepatocellular carcinoma (HCC), phytosomal nanotherapeutics improve the targeted delivery and bioavailability of phytochemicals to tumor cells, thereby reducing systemic toxicity and increasing therapeutic efficacy. In order to address the intricate molecular processes implicated in HCC, this strategy is essential. Keywords: hepatocellular carcinoma, liver cancer, phytosome, nanocarrier, clinical trials Graphical Hepatocellular Carcinoma (HCC) constitutes a global burden, ranking as the third common disease of cancer-related to dies after colorectal and respiratory cancers. It was also the sixth diagnosed cancer, with an estimated 865,269 new cases and 757,948 deaths (GLOBOCAN 2022) from liver cancer occurring in the year 2022. 1,2 The projection indicates the number of new HCC cases per year will be rise by 55% from 2020 to 2040, potentially reaching 1.4 million diagnoses by 2040. Additionally, it is estimated that 1.4 million people will be could die from hepatic cancer in 2040, which would be a 56.4% increase from 2020. 3 Liver cancer and its incidence depend upon multiple factors such as demographic displacements, lifestyle changes, and environmental segments. Increasing incidences of obesity and metabolic disorders across the globe are laying a foundation for the prevalence of liver cancer in the future. Moreover, the regular use of some drugs typically used to treat hepatitis B and C is another cause seen rising chances for HCC. 4 HCC has limited treatment options and often is not discovered until a late stage, which can have a big impact on patient outcomes. Meanwhile, liver transplantation is a viable option for the treatment of HCC and as a finally, this treatment has become standardness for many patients with liver cancer. The use for liver transplant increased life expectancy and cured this disease. 5 The United States Food and Drug Administration (USFDA) has launched Sorafenib also known as Nexavar ® (Bayer Pharmaceuticals), as a first-line chemotherapeutic agent for the treatment of hepatic between 2000 and 2007. Despite the other treatment options that have been relatively ineffective and associated with severe side effects, including chemotherapy or radiation therapy alone or in combination with surgical resection. 6 The management of HCC becomes intricate due to various reasons including the intricacies related to the disease itself and limitations present in conventional approaches. Furthermore, HCC had shown to be diagnosed late because of the clinical silence during the early period in many cases and frequently presented at an advanced stage which resulted from delay in treatment Moreover, the outcome of the treatment may be affected by that its terminal diagnosis decreases therapeutic possibilities. HCC tumors are equally challenging and complicated as they exhibit heterogeneity. 7,8 The intrinsic variety of HCC tumors makes it difficult to create a single therapeutic strategy that works for every subtype. Since no two tumors are exactly comparable due to this heterogeneity, developing a therapeutic strategy that works for all tumors is challenging. 9 For HCC, a many numbers of patients are treated with traditional treatment modalities including surgeries, and hepatic transplantation, such as transarterial chemo-embolization (TACE). However, these techniques are restricted to the dimensions and location of the liver tumor and to more systemic liver function. 10 There are limitations to these treatments which point out -Abstract Truncated-
oncology